CompoAtlas

COMPLEXE SOMMEIL

Food supplement declared in France, declaration No 2022-8-862

COMPLEXE SOMMEIL is a food supplement declared in France. Status: retrait du marché annoncé pour le 5 April 2027. 1 point in its composition requires a check (prohibited substance, dose or novel food).

Brand
not provided
Food business operator placing the product on the market
Biofarma France (Sérent - Laboratoire Pierre Caron)
Status
Retrait du marché annoncé pour le 5 April 2027
Form
Gélule
Daily dose
2 gélules
Directions for use
cf ci-dessous
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Enfants (moins de 12 ans), Femmes enceintes, Sous antidépresseurs, Sous traitement médicamenteux
Objectives stated by the manufacturer (these are not authorised claims)
Sommeil

Declaration 235999, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Melissa officinalis L.FeuilleExtrait sec aqueux375 mg
Griffonia simplicifolia (DC.) Baill.GraineExtrait sec hydroalcoolique100 mg
Passiflora incarnata L.Parties aériennesExtrait sec aqueux100 mg
Eschscholzia californica Cham.Parties aériennesExtrait sec aqueux50 mg

Other active ingredients

NamePer day
Mélatoninenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Oxyde de magnésiumMagnésium250 mg300 mg
NicotinamideNicotinamide (vitamine B3)900 mg54 mg
Chlorhydrate de pyridoxineVitamine B612 mg2 mg

Additives

E464, E414, E470b

Other ingredients

maltodextrine

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé aux enfants, aux adolescents, aux femmes enceintes et allaitantes, ainsi qu’aux personnes souffrant de maladies inflammatoires ou auto-immunes, aux personnes épileptiques, asthmatiques ou souffrant de troubles de l’humeur, du comportement ou de la personnalité, ainsi qu’en cas de prise simultanée d’antidépresseurs compte tenu de sa teneur en 5-HTP. Déconseillé en cas de prise simultanée de médicaments. En raison du risque de somnolence, il est recommandé de ne pas conduire de véhicules, ni de manipuler de machines-outils dans les heures qui suivent la prise de mélatonine. Demander l’avis de votre médecin et /ou pharmacien.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Other declarations with the same name

This name is used by more than 10 declarations from different companies, so it does not identify one product. See every declaration with this name.

Enter to analyse, Shift+Enter for a new line